Conning Inc. Sells 158 Shares of Zoetis Inc. $ZTS

Conning Inc. cut its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 5.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,871 shares of the company’s stock after selling 158 shares during the period. Conning Inc.’s holdings in Zoetis were worth $448,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Summit Place Financial Advisors LLC increased its holdings in shares of Zoetis by 0.8% in the second quarter. Summit Place Financial Advisors LLC now owns 19,293 shares of the company’s stock worth $3,009,000 after buying an additional 149 shares during the period. Aberdeen Group plc grew its position in Zoetis by 5.4% during the 2nd quarter. Aberdeen Group plc now owns 1,155,604 shares of the company’s stock worth $179,720,000 after acquiring an additional 59,245 shares during the last quarter. Davis Rea LTD. increased its stake in Zoetis by 96.6% in the 2nd quarter. Davis Rea LTD. now owns 41,239 shares of the company’s stock worth $6,431,000 after purchasing an additional 20,268 shares during the period. Blue Zone Wealth Advisors LLC boosted its stake in shares of Zoetis by 8.8% during the second quarter. Blue Zone Wealth Advisors LLC now owns 32,626 shares of the company’s stock valued at $5,088,000 after purchasing an additional 2,646 shares during the period. Finally, PDS Planning Inc boosted its stake in shares of Zoetis by 11.6% during the second quarter. PDS Planning Inc now owns 2,607 shares of the company’s stock valued at $407,000 after purchasing an additional 270 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 1.6%

ZTS opened at $141.05 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The stock has a market cap of $62.51 billion, a PE ratio of 24.28, a PEG ratio of 2.26 and a beta of 0.90. The business has a 50 day moving average of $149.24 and a 200-day moving average of $154.41.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is 34.42%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZTS. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $196.71.

Get Our Latest Report on ZTS

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.